| Outcome Measures: |
Primary: Mean change in HbA1c, HbA1c: Glycated Hemoglobin, From baseline to end of week 24 | Secondary: Change in HbA1c, From baseline to end of week 12|Change in fasting blood glucose, From baseline to end of week 6, week 12, week 24|Change in postprandial glucose level, From baseline to end of week 6, week 12, week 24|Occurrence of Hypoglycemic events, From baseline up to 24 weeks|Severity of Hypoglycemic events, From baseline up to 24 weeks|Occurrence of Gastrointestinal intolerance, From baseline up to 24 weeks|Occurrence of other AEs relating to tolerability, From baseline up to 24 weeks|Change in patient tolerability to therapy, From baseline up to 24 weeks|Mean change in body weight, From baseline to end of week 12, week 24|Mean change in lipid profile, From baseline up to 24 weeks|Descriptive analysis of starting dose and final dosing, From baseline up to 24 weeks|Descriptive analysis of time taken for full dose titration, From baseline up to 24 weeks|Descriptive analysis of PPG recorded at each visit, From baseline up to 24 weeks|Descriptive analysis of FBG recorded at each visit, From baseline up to 24 weeks|Descriptive analysis of HbA1c recorded at each visit, From baseline up to 24 weeks|Descriptive analysis of body weight recorded at each visit, From baseline up to 24 weeks|Descriptive analysis of actual duration of treatment with acarbose/metformin FDC before addition of other anti-diabetes drugs, From baseline up to 24 weeks|Descriptive analysis of time of addition of the other anti-diabetes drug, From baseline up to 24 weeks|Descriptive analysis of reason of addition of the other anti-diabetes drug, From baseline up to 24 weeks|Descriptive analysis of reason for discontinuation of acarbose/metformin FDC treatment, From baseline up to 24 weeks|Descriptive analysis of adverse events (AEs), AEs assessed and recorded by the physician on the AE report form attached to the case report form, From baseline up to 24 weeks
|
